|
業務類別
|
Biotechnology |
|
業務概覽
|
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States. |
| 公司地址
| 80 Guest Street, Boston, MA, USA, 02135 |
| 電話號碼
| +1 617 500-8864 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.aurabiosciences.com |
| 員工數量
| 113 |
| Dr. Janet Jill Hopkins, M.D. |
Chief Medical Officer and President, Research and Development |
美元 551.25K |
20/04/2026 |
| Ms. Amy Elazzouzi |
Senior Vice President, Finance and Principal Accounting Officer |
-- |
30/03/2026 |
| Mr. Mark Plavsic, D.V.M.,PhD |
Chief Technology Officer |
-- |
20/04/2026 |
| Mr. Conor Kilroy |
Chief Legal Officer and Secretary |
-- |
20/04/2026 |
| Mr. Anthony S. Gibney |
Chief Financial Officer and Chief Business Officer |
美元 345.91K |
20/04/2026 |
| Dr. Elisabet de los Pinos, PhD |
Director, President and Chief Executive Officer |
美元 645.48K |
20/04/2026 |
|
|
| Dr. Sapna Srivastava, PhD |
Independent Director |
20/04/2026 |
| Ms. Teresa Marie Bitetti |
Independent Director |
20/04/2026 |
| Mr. Antony C. Mattessich |
Independent Director |
20/04/2026 |
| Mr. Karan S. Takhar |
Independent Director |
20/04/2026 |
| Dr. Elisabet de los Pinos, PhD |
Director, President and Chief Executive Officer |
20/04/2026 |
| Mr. David Johnson |
Chairman of the Board |
20/04/2026 |
| Dr. Giovanni Mariggi, PhD |
Independent Director |
20/04/2026 |
|
|
|
|
